Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.

What Was Tested

The paper reports a study of Human Growth Hormone in the context of hyperparathyroidism, published as a randomized controlled trial.

Prader-Willi syndrome (PWS) is a complex genetic disorder characterised by mild mental retardation and distinct physical, behavioural, and psychiatric features.

One of the cardinal symptoms is excessive eating, which--if left untreated--leads to extreme obesity.

Who Took Part

According to the abstract, 9 men were involved.

By PubMed's age tags, the people studied were teenagers and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and placebo-controlled study.

Because people in this Human Growth Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Human Growth Hormone study: the men and staff both knew the treatment.

Some men received a placebo instead of Human Growth Hormone, giving a reference point.

Weight, BMI, oxytocin (baseline only), leptin, Neuropeptide Y (NPY), and ghrelin were evaluated at baseline and after 6 and 12 months.

What Was Measured

In the present study the researchers have examined circulating levels of peptides with documented association to hyperphagia in young adults with PWS.

Genetic testing was performed in all patients and in 11 the diagnosis was confirmed.

PubMed files the paper under topics including Body Mass Index, Eating, Fasting, Ghrelin, Human Growth Hormone, Hyperphagia and Leptin.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Human Growth Hormone in 9 men in people with hyperparathyroidism.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, Hyperparathyroidism research.